Equibles does not estimate personal net worth.
Get an email with a short summary when Sionna Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SION alertsElena Ridloff is recorded as CFO at Sionna Therapeutics, Inc. (SION) and Board Member at Kymera Therapeutics, Inc. (KYMR) since January 1, 2021. The newest filing on record that lists Elena Ridloff as CFO at Sionna Therapeutics, Inc. (SION) is dated April 27, 2026. The newest filing on record that lists Elena Ridloff as Board Member at Kymera Therapeutics, Inc. (KYMR) is dated April 29, 2026. Earlier roles on record: CFO at Acadia Pharmaceuticals Inc (ACAD) until September 10, 2021. Sionna Therapeutics, Inc. reported in an 8-K filed September 14, 2026 that Elena Ridloff was appointed Chief Business Officer, effective September 16, 2026. The proxy statement of Sionna Therapeutics, Inc. reports total compensation of $2,857,367 for Elena Ridloff in fiscal 2025, including a base salary of $506,677. Disclosed compensation is on record for 6 fiscal years. Elena Ridloff has spoken on 6 earnings calls and 2 other investor events across 2 companies, most recently for Sionna Therapeutics, Inc. on November 9, 2026. Those appearances were for Acadia Pharmaceuticals Inc (ACAD) and Sionna Therapeutics, Inc. (SION). Sionna Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Kymera Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Elena Ridloff spoke on are classified in the Healthcare sector. Other leadership on record at Sionna Therapeutics, Inc. includes Michael Cloonan (CEO), H. Edward Fleming (Board Member), Joanne Louise Viney (Board Member) and 2 others.
“Elena Ridloff, the Company's Chief Financial Officer, assumed the additional role of Chief Business Officer”
“We've really prioritized our clinical investments in the dual combination going forward and resized the company to support that. So we have extended our cash runway into the second half of 2029.”
“So maybe just to lay a little foundation at Siona, we're trying to do something very different in targeting CF. We're targeting MBD1 and stabilizing MBD1, which is the region of the CFTR protein where the Delta 508 mutation sits and 90% of patients with CF have that mutation.”
“Today, I'll discuss our second quarter 2021 results and our updated 2021 financial outlook. Please turn to slide 21. In the second quarter of 2021, we recorded $115.2 million in net sales, an increase of approximately 5% compared to $110.1 million of net sales in Q2 of 2020.”
“Today, I'll discuss our first quarter 2021 results and our updated 2021 financial outlook. Please turn to Slide 20. In the first quarter of 2021, we recorded $106.6 million in net sales, an increase of approximately 18% compared to $90.1 million of net sales in Q1 of 2020.”
“Today, I'll discuss our fourth quarter and full-year 2020 results and our 2021 financial outlook. Please turn to Slide 9. In the quarter, we recorded $121 million in net sales, an increase of approximately 23% compared to $98.3 million in net sales in Q4 of 2019.”
SEC 8-K
2026-09-16–present
2021-01-01–present
Last confirmed April 29, 2026
Start not stated–present
Last confirmed April 27, 2026
Start not stated–2021-09-10
Biotechnology · Healthcare
CFO
2026-09-16–present
Biotechnology · Healthcare
Board Member
2021-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Sionna Therapeutics, Inc. (SION) | C.F.A. Chief Financial Officer | $506,677 | $2,857,367 |
| 2024 | Sionna Therapeutics, Inc. (SION) | C.F.A. Chief Financial Officer and Head of Corporate Development | $449,946 | $1,300,647 |
| 2023 | Sionna Therapeutics, Inc. (SION) | C.F.A. Chief Financial Officer and Head of Corporate Development | $432,640 | $623,002 |
| 2021 | Acadia Pharmaceuticals Inc (ACAD) | Chief Financial Officer | $398,871 | $2,389,704 |
| 2020 | Acadia Pharmaceuticals Inc (ACAD) | Chief Financial Officer | $462,000 | $2,514,170 |
| 2019 | Acadia Pharmaceuticals Inc (ACAD) | Chief Financial Officer | $444,026 | $1,990,867 |
